This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Initial anticoagulation

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

initial and long term anticoagulation (first 3-6 months)

Initial phase of treatment, which include intensified anticoagulants is followed by long term anticoagulants for 3-6 months in majority of patients (1)

  • the goal is to rapidly extinguish thrombin and fibrin clot generation
  • multiple therapeutic options are available
    • conventional treatment involves parenteral heparin bridging to vitamin K antagonists (VKAs)
      • LMWH is usually preferred due to disadvantages of intravenous unfractionated heparin
        • inter-individual dose requirements that make close laboratory therapeutic monitoring a necessity
        • 8-10-fold higher risk for heparin-induced thrombocytopenia (HIT) than LMWH

      • UFH may be preferable in
        • patients with high bleeding risk
        • special patient populations e.g.
          • morbidly obese (BMI >= 40 kg/M2) and underweight patients (weight < 50 kg)
          • patients with severe renal impairment or unstable renal function (creatinine clearance <30 mL/min)

      • fondaparinux can also be employed as a parenteral agent for hospitalized patients in whom transition to a vitamin K antagonist (VKA) is anticipated

      • vitamin K antagonist (VKA) therapy can begin as soon as therapeutic levels of UFH/LMWH are achieved
        • parenteral therapy with UFH or LMWH should continue for at least 5 days of overlap and until an INR of 2 or more is achieved for 24 h

    • direct oral anticoagulants (DOACs)/ novel non-anti-vitamin K antagonist anticoagulants (NOACs)
      • have recently emerged as a treatment option for DVT
        • dabigatran and edoxaban therapy must include initial 7- 9 days treatment with a parenteral agent prior to beginning these agents.
        • apixaban and rivaroxaban can be used as a 'single drug approach' (without initial parenteral therapy)
      • is the preferred first-line anticoagulant therapy in non-cancer patients with proximal DVT
      • disadvantages include
        • longer elimination half-lives (7- 15 h) than UFH or LMWH
        • could accumulate in patients with suboptimal renal (estimated creatinine clearance <30 mL/min) or hepatic function

  • thrombolytic therapy
    • can be used in patients with acute extensive proximal lower extremity DVT or patients with proximal DVT that fails to respond to initial anticoagulation

  • vena cava filter
    • used when anticoagulation is absolutely contraindicated in patients with newly diagnosed proximal DVT
      • retrievable filter should be removed rapidly as soon as contraindications are resolved and anticoagulation can be started (2,3)

NICE suggest (4):

  • measure baseline full blood count, renal and hepatic function, PT and APTT but start anticoagulation before results available. Review and if necessary act on results within 24 hours
  • offer anticoagulation for at least 3 months. Take into account contraindications, comorbidities and the person’s preferences
  • after 3 months (3 to 6 months for active cancer) assess and discuss the benefits and risks of continuing, stopping or changing the anticoagulant with the person. See long-term anticoagulation for secondary prevention(linked item)

Anticagulatant considerations considered in terms of:

  • No renal impairment, active cancer, antiphospholipid syndrome or haemodynamic instability
    • offer apixaban or rivaroxaban
    • if neither suitable, offer one of:
      • LMWH for at least 5 days followed by dabigatran or edoxaban
      • LMWH and a VKA for at least 5 days, or until INR at least 2.0 on 2 consecutive readings, then a VKA alone

  • Renal impairment (CrCl estimated using the Cockcroft and Gault formula; see the BNF)
    • CrCl 15 to 50 ml/min, offer one of:
      • apixaban
      • rivaroxaban
      • LMWH for at least 5 days then
        • edoxaban or
        • dabigatran if CrCl >= 30 ml/min
      • LMWH or UFH and a VKA for at least 5 days, or until INR at least 2.0 on 2 consecutive readings, then a VKA alone

    • CrCl < 15 ml/min, offer one of:
      • LMWH
      • UFH
      • LMWH or UFH and a VKA for at least 5 days, or until INR at least 2.0 on 2 consecutive readings, then a VKA alone
    • Note cautions and requirements for dose adjustments and monitoring in SPCs. Follow local protocols, or specialist or MDT advice
  • Active cancer (receiving antimitotic treatment, diagnosed in past 6 months, recurrent, metastatic or inoperable
    • Consider a DOAC
    • if a DOAC is not suitable, consider one of:
      • LMWH
      • LMWH and a VKA for at least 5 days or until INR at least 2.0 on 2 consecutive readings, then a VKA alone
    • Offer anticoagulation for 3 to 6 months. Take into account tumour site, drug interactions including cancer drugs, and bleeding risk
  • Antiphospholipid syndrome (triple positive, established diagnosis)
    • Offer LMWH and a VKA for at least 5 days or until INR at least 2.0 on 2 consecutive readings, then a VKA alone

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.